Sökning: onr:"swepub:oai:gup.ub.gu.se/170097" >
Once-daily fluticas...
Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids
-
Bleecker, E. R. (författare)
-
Bateman, E. D. (författare)
-
Busse, W. W. (författare)
-
visa fler...
-
Woodcock, A. (författare)
-
Frith, L. (författare)
-
House, K. W. (författare)
-
Jacques, L. (författare)
-
Davis, A. M. (författare)
-
Haumann, B. (författare)
-
- Lötvall, Jan, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Krefting Research Centre
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2012
- 2012
- Engelska.
-
Ingår i: Annals of Allergy Asthma & Immunology. - : Elsevier BV. - 1081-1206. ; 109:5
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Fluticasone furoate (FF) is an inhaled corticosteroid (ICS) with 24-hour activity in development as a once-daily treatment for the long-term management of asthma. Objective: To assess the efficacy and safety of 4 doses of once-daily FF administered using a dry powder inhaler in patients (>12 years) with moderate asthma, uncontrolled on low-dose ICS (fluticasone propionate [FP] 200 mu g/day or equivalent). Methods: This double-blind, placebo-controlled, dose-ranging study randomized 622 patients to 1 of 6 treatments: FF (100, 200, 300, or 400 mu g) once daily in the evening, FP 250 mu g twice daily (active control), or placebo for 8 weeks. The primary endpoint was the change from baseline in predose evening forced expiratory colume in 1 second (FEV1) at week 8. Results: At week 8, relative to placebo, all doses of FF once daily and FP twice daily demonstrated significantly (P < .001) greater increases from baseline and greater than 200-mL increases in predose FEV1. There was no evidence of a dose-response relationship between FF doses. Improvement with once-daily FF was similar to or greater than that for twice-daily FP. Secondary efficacy endpoint findings generally supported the efficacy of FF 100 to 400 mu g once daily, although statistically significant improvements versus placebo in symptom-free 24-hour periods were only reported for FF 400 mu g. There were few withdrawals due to lack of efficacy. Oral candidiasis was reported in 0 to 4% of patients; 24-hour urinary cortisol excretion ratios were similar across active treatment groups and not significantly different from placebo. Conclusion: FF 100 to 400 mu g once daily in the evening is effective and well tolerated in patients with asthma uncontrolled on low-dose ICS, with 100 mu g and 200 mu g, considered the most applicable doses in this asthma population. Trial Registration: clinicaltrials.gov Identifier: NCT00603278. (C) 2012 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine (hsv//eng)
Nyckelord
- nocturnal asthma
- uncontrolled asthma
- persistent asthma
- research-program
- reference values
- single inhaler
- budesonide
- propionate
- salmeterol
- exacerbations
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bleecker, E. R.
-
Bateman, E. D.
-
Busse, W. W.
-
Woodcock, A.
-
Frith, L.
-
House, K. W.
-
visa fler...
-
Jacques, L.
-
Davis, A. M.
-
Haumann, B.
-
Lötvall, Jan, 19 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
- Artiklar i publikationen
-
Annals of Allerg ...
- Av lärosätet
-
Göteborgs universitet